1ADHealth CareCompany Update10 August 2026· 2 min read
AdAlta (ASX: 1AD) Reports Continued Survival in EW-001 Study
All five EW-001 patients still under follow-up in March remained alive and on study in July. Higher-dose data support AdAlta’s planned Australian Phase 1 trial.